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Abstract
Background: Models of collaborative care and consultation liaison propose organizational changes to improve the
quality of care for people with common mental disorders, such as anxiety and depression. Some literature suggests
only short-term positive effects of consultation liaison on patient-related outcomes, whereas collaborative care
demonstrates both short-term and long-term positive effects. To our knowledge, only one randomized trial has
compared the effects of these models. Collaborative care was superior to consultation liaison in reducing symptoms of
depression for up to 3months, but the authors found no difference at 9-months' follow-up. The Collabri Flex Trial for
Depression and the Collabri Flex Trial for Anxiety aim to compare the effects of collaborative care with those of a form
of consultation liaison that contains potential contaminating elements from collaborative care. The trials build on
knowledge from the previous cluster-randomized Collabri trials.
Methods: Two randomized, investigator-initiated, parallel-group, superiority trials have been established: one
investigating the effects of collaborative care vs consultation liaison for depression and one investigating the effects of
collaborative care vs consultation liaison for generalized anxiety, panic disorder and social anxiety disorder at 6-months'
follow-up. Participants are recruited from general practices in the Capital Region of Denmark: 240 in the depression trial
and 284 in the anxiety trial. The primary outcome is self-reported depression symptoms (Beck Depression Inventory (BDI-
II)) in the depression trial and self-reported anxiety symptoms (Beck Anxiety Inventory (BAI)) in the anxiety trial. In both
trials, the self-reported secondary outcomes are general psychological problems and symptoms (Symptom Checklist 90-
Revised), functional impairment (Sheehan Disability Scale) and general well-being (World Health Organization-Five Well-
Being Index). In the depression trial, BAI is an additional secondary outcome, and BDI-II is an additional secondary
outcome in the anxiety trial. Explorative outcomes will also be collected.
Discussion: The results will supplement those of the cluster-randomized Collabri trials and provide pivotal information
about the effects of collaborative care in Denmark.
Trial registration: ClinicalTrials.gov, NCT03113175 and NCT03113201. Registered on 13 April 2017.
Keywords: Collaborative care, Anxiety, Depression, Randomized controlled trial, General practice, Cognitive behavioral
therapy
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Background
Common mental disorders, such as anxiety and depres-
sion, are prevalent in the general population [1–4], con-
tribute to high levels of morbidity and have great impact
on the economy [5, 6]. According to the World Health
Organization, management of these conditions should
be integrated into primary care [7]. Nevertheless, it is
recognized that this group of patients is both underdiag-
nosed and undertreated in primary care [1, 8–11]. Lack
of coordination between sectors and limited availability
of evidence-based treatment, such as psychotherapy, are
some of the explanations for these deficiencies in
Denmark [12].
To improve the quality of care for people with depres-
sion in primary care, early research focused on enhan-
cing the primary-care providers’ knowledge and skills.
Interventions such as short-term courses and passive
dissemination of guidelines were generally unsuccessful
in showing effects on patient outcomes [13, 14]. Later,
consultation liaison interventions focused on specialist
support and assistance. There is no consensus about the
exact definition or content of mental health consultation
liaison in the literature and the limited evidence seems
inconsistent [15–17]. However, consultation liaison is
broadly characterized by a mental-health worker provid-
ing specialist consultative support to a primary-care pro-
vider who has a central role in delivering mental health
care. The extent of contact between the mental-health
worker and the patient seems to vary according to differ-
ent models of consultation liaison [17]. Using broad in-
clusion criteria, a Cochrane review found no statistically
significant difference in symptoms from 3 to 12 months'
follow-up between consultation liaison and standard
care groups [17]. However, a positive effect of consult-
ation liaison was found on mental health for up to 3
months and on treatment satisfaction and adherence for
up to 12 months for different mental disorders, particu-
larly depression [17]. Another systematic review and
meta-analysis found no statistically significant improve-
ments regarding antidepressant use or outcomes for de-
pression in the short or long term for patients with
depression [16]. The authors included only consultation
liaison interventions characterized by no contact be-
tween the mental-health worker and the patient after
initial assessment, and therefore used a narrower defin-
ition than did the Cochrane review.
In 2006, a set of criteria was suggested for successful
system-level approaches for management of depression
in primary care. These criteria are commonly referred to
as criteria for collaborative care. They cover a multi-pro-
fessional approach to patient care with enhanced com-
munication between professionals, where the treatment
is based on a structured management plan that includes
close, scheduled follow-up [18]. Using these criteria, a
Cochrane review from 2012 found that collaborative
care was associated with significant improvement for up
to 2 years in depression and anxiety outcomes compared
with treatment as usual [19]. The impact of collaborative
care has been extensively documented for depression,
especially in the United States [19–21]; for anxiety disor-
ders, collaborative care has not been as widely studied
[19, 22]. Additionally, the available research differs
greatly in terms of context, patient characteristics and
intervention activities within the framework of collab-
orative care. Such differences potentially have an impact
on the generalizability of results to other settings, such
as Denmark [23].
In 2013, a National Health Technology Assessment
(HTA) was initiated to evaluate the effect, patient satisfac-
tion, and economic and organizational consequences of col-
laborative care in Denmark. As part of the HTA, a Danish
collaborative care model for anxiety and depression was de-
veloped. Between 2014 and early 2017 the model was tested
in the Capital Region of Denmark in four cluster-random-
ized superiority trials (the Collabri trials) comparing collab-
orative care with treatment as usual for depression,
generalized anxiety disorder, social anxiety disorder and
panic disorder [24, 25]. As collaborative care involves activ-
ities on the organizational level, such as ongoing supervi-
sion and support of the general practitioner (GP) by
mental-health specialists, cluster randomization was chosen
because of the considerable risk of control group contamin-
ation if randomization was performed on an individual level
[26]. This would be likely to occur because it would be diffi-
cult for GPs to abstain from getting supervision from the
mental-health specialists on patients in the control group.
Despite extensive efforts, too few participants were included
in the trials, especially in the control groups, which resulted
in inadequate sample sizes with unequal distribution be-
tween the two groups. These small sample sizes (around
half of what was expected) would most likely lead to under-
powered study results. To contribute satisfactorily to the
HTA, two more feasible trials were designed using individ-
ual randomization. This paper outlines the protocol for
these trials—the Collabri Flex Trial for Depression and the
Collabri Flex Trial for Anxiety. Instead of comparing col-
laborative care with treatment as usual, which would have
been preferable, the aim is to compare collaborative care
with a form of consultation liaison that contains potential
contaminating elements from collaborative care (supervi-
sion and support by mental-health specialists). Because we
assume that this contamination is difficult to avoid in the
comparison group, we acknowledge it by adding it to the
comparison group intervention. As far as we are aware,
only one study has compared collaborative care with con-
sultation liaison [27]. In that study, the population was
highly selected as participants were recruited among pa-
tients with depression in the US Veterans’ Affairs Primary
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Care. The authors found that collaborative care was super-
ior to consultation liaison in reducing symptoms of depres-
sion for up to 3months, but no difference between groups
was detected at 9months.
Based on this literature, the primary hypothesis in the
Collabri Flex Trial for Depression is that patients in the
collaborative care group will show a greater reduction in
depression symptoms after 6months compared with
patients in the consultation liaison group. The primary hy-
pothesis in the Collabri Flex Trial for Anxiety is similar:
patients in the collaborative care group will show a greater
reduction in anxiety symptoms after 6months compared
with patients in the consultation liaison group.
Methods
Design
The Collabri Flex study involves two randomized, inves-
tigator-initiated, parallel-group superiority trials: one for
the ICD-10 diagnoses of depression, and one for anxiety
(the ICD-10 diagnoses of generalized anxiety, panic dis-
order and social anxiety disorder). The aim of the de-
pression trial is to compare the effects of two
interventions: collaborative care and consultation liaison.
Similarly, the aim of the anxiety trial is to compare the
effects of collaborative care with those of consultation
liaison (see flow chart in Fig. 1).
Setting
Participants are referred to one of the two trials by their
GP. The GP practice must be based in the Capital
Region of Denmark and the GP must agree to the terms
and conditions of the study. The terms and conditions
include financial reimbursement (an amount equivalent
to around 80 USD per patient in the consultation liaison
group and 360 USD per patient in the collaborative care
group), and they are negotiated by the local branch of
the Organization of General Practitioners in Denmark
and the Capital Region of Denmark.
Participants
The inclusion and exclusion criteria for both trials are
assessed by the GP on recruitment and/or by the care
manager at a baseline diagnostic eligibility interview. Ac-
cording to the inclusion criteria, eligible participants must:
 be 18 years or older
 be able to speak Danish
 give their written consent to participate
 fulfill the diagnostic criteria for unipolar depression
(F32 and F33) according to the International
Classification of Diseases 10th edition (ICD-10) in
the depression trial, and fulfill the diagnostic criteria
for social anxiety disorder, panic disorder or
generalized anxiety disorder (F40.1, F41.0 and F41.1)
according to the ICD-10 in the anxiety trial
All diagnoses are verified at baseline by a care manager
from the Collabri Flex team using the Mini International
Neuropsychiatric Interview (MINI) (Diagnostic and Stat-
istical Manual of Mental Disorders, 4th edition) includ-
ing ICD-10 specific questions, and are confirmed by the
psychiatrist.
The Collabri Flex trials are aimed at patients in pri-
mary care. Consequently, the trials are not designed to
provide acute or highly specialized treatment. Therefore,
patients are excluded if they:
 have a high risk of suicide
 have a current psychotic condition
 have a post-traumatic stress disorder (PTSD)
 have an obsessive-compulsive disorder (OCD)
 have a bipolar affective disorder
 have a severe alcohol or substance misuse that
prevents them from participating in the Collabri
Flex intervention
 have been referred to or are recommended for
referral to secondary care treatment (mental health
center) or psychiatrist in private practice
 have been assessed by the GP as being too
somatically unstable to adhere to the treatment
 are pregnant
 have a diagnosis of dementia
To prevent parallel treatment, patients are excluded if
they will not allow treatment for anxiety or depression ac-
cording to the psychologist scheme or similar treatment
to be preceded by collaborative care treatment if they are
allocated to the group offered this. Likewise, patients are
excluded if they already receive treatment according to
the psychologist scheme or similar treatment and indicate
that they will not opt out of treatment if they are allocated
to the group offered collaborative care.
Recruitment and randomization
The GP provides oral and written information about the
study, obtains oral and written consent, and refers
patients with depression or anxiety to the trials. A care
manager contacts the patient to arrange a diagnostic eli-
gibility interview assessing the inclusion and exclusion
criteria. If the patient meets the inclusion criteria and is
not excluded, a Collabri Flex team member performs the
randomization through the Odense Patient data Explora-
tive Network (OPEN), which is an external web-based
randomization provider [28]. The allocation sequence is
computer generated and the block sizes are variable.
The randomization in both trials is stratified by former
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psychological and/or pharmacological treatment for anx-
iety or depression (yes/no). In the depression trial, an
additional stratification variable is the degree of depres-
sion as assessed in the eligibility interview (mild/moder-
ate/severe), and in the anxiety trial an additional
stratification variable is the type of anxiety disorder
assessed as the primary diagnosis (generalized anxiety
disorder/panic disorder/social anxiety disorder). The
care manager will contact the patient with information
about the result of the randomization. If the patient is
allocated to collaborative care, the care manager will
schedule the first consultation. If the patient is allocated
to the group offered consultation liaison, the GP will
continue the treatment. Ideally, the time from referral to
randomization should not exceed 3 weeks (see Table 1).
Blinding
It is not possible to ensure blinding of the allocation to
patients, their GP or the Collabri Flex team, including
care managers and psychiatrists involved in the interven-
tion activities. Researchers are blinded to allocation if
they contact patients at follow-up to collect data. This
will be relevant only if participants require help in com-
pleting self-assessment data. During the entire phase of
statistical analyses, the groups will be coded and anon-
ymized (e.g. X and Y) so that researchers are blinded.
This will also apply when writing the conclusion.
Interventions
The Collabri Flex team consists of seven full-time care
managers; they are all health-care professionals with a
Fig. 1 Flow chart of the trials
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medium-long education and have mental health care
experience and at least 1 year of certified training in CBT
or equivalent. One care manager is also the team leader
and ensures for example patient flow and quality improve-
ment implementation. A psychiatrist, equivalent to a 0.9
full-time position, is also a part of the team. Additionally,
an approved CBT supervisor provides 2 h of supervision
every 2 weeks. Care managers have attended a 1-week
introductory course to the Collabri model, which the Col-
labri Flex model builds upon. The course included a brush-
up on CBT methods. The psychiatrist also participated in
this training. All GPs are trained in the principles of collab-
orative care and the Collabri Flex model. Changes from the
Collabri model to the Collabri Flex model have been dis-
seminated through workshops prior to intervention start. A
care manager can assist a maximum of five GP practices
and hold a maximum case load of 25 patients at a time.
To ensure the internal validity and quality of the
Collabri Flex intervention, an evaluation of the fidelity
will be done after 6 months and at least once more dur-
ing the project period. The fidelity measurement ensures
that the intervention is carried out according to the
description of the Collabri Flex model and will be con-
ducted by persons who are not part of the research
group. Based on the assessments, an action plan is devel-
oped to improve fidelity.
The Collabri Flex team is employed in the mental-
health services and delivers two separate interventions:
collaborative care according to the Collabri Flex model;
and consultation liaison. The content of these interven-
tions is outlined in the following.
Collaborative care
The collaborative care model tested in the trials is based
on the former Collabri model [24, 25] and has been up-
dated to incorporate key knowledge and experiences
from the Collabri anxiety and depression trials. The
Collabri Flex model complies with the collaborative care
criteria [18, 19] in the following way:
 The model proposes a multi-professional approach
to treatment that involves a GP, a care manager and
a psychiatrist.
 The inter-professional communication is promoted
through planned, regular contact. The GP and care
manager have weekly meetings. Twice a month, the
psychiatrist provides supervision of care managers in
planning and modifying the treatment plans. They
meet individually as needed. Twice a month, care
managers receive supervision from a cognitive
behavioral therapy (CBT) supervisor. Once a month,
GPs can participate in group-based and/or
individual supervision and take part in educational
workshops on specific topics. The GP, care manager
and the psychiatrist can have joint consultations
when needed. Preferably, communication between
professionals is face to face; however, due to logistic
challenges, video-conferencing is an alternative.
Preferably, a joint recording system should be
established, but this has not been possible in the
current setting. A safe electronic communication
system is used when communication containing
person-identifiable information occurs between care
managers/psychiatrists and the GP.
 Individual treatment plans are developed based on
treatment instructions for depression, generalized
anxiety disorder, panic disorder and social anxiety
disorder taking into account the patient’s needs and
preferences. The instructions comply with the
Danish Health Authority’s Reference programs for
anxiety disorders [29] and unipolar depression in
adults [30] as well as the Danish College of General
Practitioners’ clinical guidelines for anxiety disorders
[31] and unipolar depression [32]. They include
general principles of care, stepped care algorithms,
medication algorithms, and psychoeducation and
CBT manuals. Depending on the diagnosis and
severity, patients are offered treatment modalities
according to a stepped care algorithm, which offers
stepwise intensification of treatment efforts if no or
limited treatment response is achieved [29, 30, 32]
(see Fig. 2). The treatment modalities are:
manualized psychoeducation either alone or as a
part of CBT, individual CBT (up to 12 sessions
depending on the diagnosis) and/or medication.
Additionally, all patients are offered supplementary
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure: enrolment and data collection
Baseline t−1
(0–3 weeks)
Randomization t0 6-month follow-up t1
Informed consent x
Eligibility interview x
Allocation x
Questionnaire data x x
Register data x x
Data on intervention activities x Continuous data collection throughout the intervention
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disease-specific information material and a self-
management book based on the Chronic Disease
Self-Management Program (CDSMP) [33] developed
for people with anxiety and depression.
 The care manager provides close scheduled follow-up
of treatment progression including monitoring and
reassessment to ensure timely changes in treatment
plans. Monitoring occurs every 2 weeks or more
frequently depending on the severity of disease. When
medication is initiated, closer monitoring occurs.
Reassessments take place at least once a month, at
every step up and at the end of treatment.
Experiences from the Collabri trials show differences
between GPs in terms of interest in the treatment man-
agement. Consequently, the Collabri Flex model was
developed to accommodate the needs of the GPs, thus
making the GP role flexible. Apart from the somatic
evaluation and pharmacological treatment, the GP can
pass on the treatment responsibility to the psychiatrist.
If this is the case, it is agreed under which circum-
stances the GP is involved. As a minimum, the GP is
informed about and approves the treatment plan and
potential changes.
The model is adapted to the Danish health-care set-
ting by incorporating the possibility of referral to the
existing psychologist scheme if there is no or minimal
effect of CBT and the possibility of coordination with
relevant social workers in the municipalities. Relatives/
friends are offered disease-specific written information
material including relevant links and contact details for
further information and advice. It is also possible for a
relative/friend to attend a care manager consultation.
The model incorporates patient involvement activities,
especially with the aim of facilitating shared decision-
making, and strives to engage patients in self-manage-
ment of their disease.
It is the intention that patient consultations take place
in the GP’s clinic; however, due to logistic challenges,
not all GPs have the capacity. In these cases, care man-
agers can meet patients in community health centers,
mental-health centers or other places in agreement with
the patient and the GP.
The estimated average duration of the collaborative
care intervention is 4 months, depending on the severity
of disease and any need to intensify treatment (step up).
There is no predefined minimum or maximum duration
of the intervention.
Fig. 2 Stepped care model showing treatment modalities offered according to diagnosis and step. CBT cognitive behavioral therapy, GAD
generalized anxiety disorder, PD panic disorder, SAD social anxiety disorder
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Consultation liaison
Consultation liaison performed in the present trials falls
under a narrow definition as suggested by Cape et al.
[16]: the Collabri Flex team can provide guidance to the
GP but does not have any treatment-related contact with
patients after the diagnostic assessment. All GPs are
encouraged to participate in the monthly supervision
and educational activities facilitated by the psychiatrist.
In addition to the scheduled meetings, the GPs can con-
sult the Collabri Flex team about patient-specific con-
cerns regardless of the patient’s allocation. For example,
this could involve diagnostic-related, treatment-related
or referral-related guidance and support. For patients
allocated to consultation liaison, their GP maintains the
treatment responsibility and continues to manage their
care. GPs can use disease-specific guidelines from the
Danish Health Authority and the Danish College of
General Practitioners [29–32]. If relevant, GPs can
prescribe medication and provide a limited number of
therapy sessions. However, they can only provide ther-
apy if they attend supervision [34]. It is estimated that
only around one-third of GPs in Denmark can provide
therapy [12, 35, 36]. GPs can refer patients to an inde-
pendent psychologist (partly publicly subsidized), an
independent psychiatrist (fully publicly subsidized) or
mental-health services (fully publicly subsidized). Pa-
tients with mild to moderate anxiety (including general-
ized anxiety, panic disorder or social anxiety disorder)
and aged between 18 and 38 years and all patients with
mild to moderate depression can attend up to 24 ses-
sions of partly publicly subsidized therapy if they see an
independent psychologist [34]. Mental-health services
offer outpatient treatment including diagnostic assess-
ment, pharmacological- and non-pharmacological treat-
ment involving up to 14 sessions of therapy in groups or
seven individual sessions [37–39]. Similarly, outpatient
treatment is part of the Collabri Flex model because it
constitutes the last step in the stepped care models (see
Fig. 2). Accessible treatment can vary between general
practices as guidelines provide only recommendations
for treatment; therefore, the estimated duration of treat-
ment can vary accordingly.
Data collection and data management
Data will consist of information obtained by the Collabri
Flex team (from baseline throughout the study period),
self-reported questionnaire data and register data.
The baseline diagnostic eligibility interview is supervised
by and delegated by the psychiatrist. The diagnostic as-
sessment is based on the Mini International Neuropsychi-
atric Interview (MINI) [40], in which all care managers
have received extensive training. The psychiatrist is always
consulted to discuss the assessment and clinical impres-
sion. If there is disagreement between the result of the
diagnostic assessment and the GP’s referral diagnosis, the
psychiatrist contacts the GP to agree on the primary diag-
nosis and potential secondary diagnoses. In connection
with the diagnostic assessment, the care manager obtains
additional baseline information using the Standardized
Assessment of Personality Abbreviated Scale (SAPAS)
[41] and, if relevant, the Attention-Deficit/Hyperactivity
Disorder Symptom Checklist for Adults (Adult ADHD
Self-report Scale (ASRS)) [42]. Self-reported question-
naires will be completed electronically before the diagnos-
tic assessment and 6months after randomization.
Diagnostic assessment data, intervention-specific data
and self-reported questionnaire data are collected
through and stored in the electronic system REDCap
[43], which is the data management system required by
the Capital Region of Denmark. Other data, such as data
extractions for quality assurance, are stored in entry-re-
stricted files on secured and logged servers. Blinding will
be maintained.
Outcomes
In the depression trial, the primary outcome is symp-
toms measured by the Beck Depression Inventory (BDI-
II) [44]. The BDI-II is a self-reported 21-item general de-
pression questionnaire, measuring depression symptoms
during the past 14 days. Symptoms are rated on a 4-
point Likert scale ranging from 0 to 3. In a review of the
psychometric properties of the BDI-II, the authors re-
ported a high internal consistency (Cronbach’s α ranging
from 0.83 to 0.96) and a test–retest reliability (Pearson’s
r) ranging from 0.73 to 0.96 [45]. In primary care pa-
tients, the questionnaire has shown reliable and intern-
ally consistent scores [46].
In the anxiety trial, the primary outcome is symptoms
measured by the Beck Anxiety Inventory (BAI) [47]. The
BAI is a self-reported 21-item general anxiety question-
naire, measuring anxiety symptoms during the past
week. Symptoms are rated on a 4-point Likert scale ran-
ging from 0 (never) to 3 (almost all the time). The ques-
tionnaire has demonstrated high internal consistency
(Cronbach’s α = 0.92) and a 1-week test–retest reliability
of 0.75 in a group of outpatients mainly with anxiety or
depression [48]. In a primary care setting, the BAI has
been shown to reflect the severity of anxiety in patients
with different anxiety disorders [49].
In both trials, the self-reported secondary outcomes
are general psychological problems and symptoms
measured by the Symptom Checklist (SCL-90-R) [50],
functional impairment measured by the Sheehan Disabil-
ity Scale (SDS) [51–53] and well-being measured by the
World Health Organization-Five Well-Being Index
(WHO-5) [54, 55]. In the anxiety trial, the BDI-II is an
additional secondary outcome, and the BAI is an
additional secondary outcome in the depression trial.
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The SCL-90-R is a questionnaire designed to assess a
broad range of general psychological problems and
symptoms. This multi-dimensional questionnaire con-
sists of 90 items rated on a 5-point Likert scale ranging
from 0 (not at all) to 4 (extremely). The items are di-
vided into nine subscales (depression, anxiety, phobic
anxiety, obsession/compulsion, hostility, somatization,
interpersonal sensitivity, paranoid ideation and psychoti-
cism) from which the joint measure, the Global Severity
Index (GSI), can be calculated as the average score of
the 90 items.
The SDS includes three items and measures functional
disability in relation to work, social and family life. For
each item there are 11 potential responses reflecting the
degree of impairment, ranging from 0 (not at all) to 10
(extremely). A total score ranging from 0 (not impaired)
to 30 (highly impaired) can be calculated.
The WHO-5 includes five items measuring the experi-
ence of positive psychological well-being. Each item is
rated from 0 (not present) to 5 (constantly present) on a
6-point Likert scale.
Explorative outcomes in both trials are self-reported
health-related quality of life measured by the EuroQol Five
Dimensions Questionnaire (EQ-5D-3 L) [56]; self-efficacy
measured by the Personal Control subscale from the Ill-
ness Perception Questionnaire Revised (IPQ-R) [57] and
two subscales (Obtain Help from Community, Family,
Friends Scale and Control/Manage Depression Scale) from
the Chronic Disease Self-Efficacy Scales [58]; experience
of support in personal recovery measured by INSPIRE
[59]; general satisfaction with treatment measured by the
Client Satisfaction Questionnaire (CSQ-8) [60, 61]; sick
leave; employment; and outpatient mental-health services
obtained from registers (see Table 2 and Fig. 3 for an
Table 2 Outcomes, data source and time for data collection
Data source Outcome Baseline 6-month
follow-up
Questionnaire Anxiety symptoms measured by the Beck
Anxiety Inventory (BAI)
Primary outcome in the anxiety trial,
secondary outcome in the depression
trial
x x
Questionnaire Depression symptoms measured by the
Beck Depression Inventory (BDI-II)
Primary outcome in the depression trial,
secondary outcome in the anxiety trial
x x
Questionnaire Functional impairment measured by the
Sheehan Disability Scale (SDS)
Secondary outcome x x
Questionnaire General psychological problems and symptoms
measured by the Symptom Checklist (SCL-90-R)
Secondary outcome x x
Questionnaire Psychological general well-being measured by
the World Health Organization-Five Well-being
Index (WHO-5)
Secondary outcome x x
Questionnaire Self-efficacy related to symptoms measured by
the Personal Control subscale from the Illness
Perception Questionnaire Revised (IPQ-R)
Explorative outcome x x
Questionnaire Self-efficacy related to management of disease
measured by the Control/Manage Depression
subscale from the Chronic Disease Self-Efficacy Scales
Explorative outcome x x
Questionnaire Self-efficacy related to support from others measured
by the Obtain Help from Community, Family, Friends
subscale from the Chronic Disease Self-Efficacy Scales
Explorative outcome x x
Questionnaire Health-related quality of life measured by the EuroQol
five-dimension three-level version of health-related
quality of life (EQ-5D-3L)
Explorative outcome x x
Questionnaire Satisfaction with treatment measured by the Client
Satisfaction Questionnaire (CSQ-8)
Explorative outcome x
Questionnaire Feeling of being supported in personal recovery by the primary
health-care provider measured by the INSPIRE measure
Explorative outcome x
DREAM
database
Sick-leave benefit (yes/no) at follow-up and weeks on
sick-leave benefit from baseline to follow-up
Explorative outcomes x x
DREAM
database
Employment (yes/no) at follow-up and weeks in
employment from baseline to follow-up
Explorative outcomes x x
National
Patient
Register
Mental-health outpatient contacts from baseline to follow-up Explorative outcome x x
DREAM Danish Register for Evaluation of Marginalization
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overview of primary, secondary and explorative out-
comes). The EQ-5D-3 L measures health-related quality
of life in five domains: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. The assessment
also contains a visual analog scale ranging from 0 (worst
imaginable health status) to 100 (best imaginable health
status). The IPQ-R consists of 12 subscales and the Per-
sonal Control subscale is a six-item scale reflecting a per-
son’s beliefs about their ability to affect own symptoms.
The items are rated on a 5-point Likert scale ranging from
Fig. 3 Full Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. BAI Beck Anxiety Inventory, BDI-II Beck Depression
Inventory II, CSQ-8 Client Satisfaction Questionnaire with eight questions, EQ-5D-3 L EuroQol five-dimension three-level version of health-related quality
of life, IPQ-R Illness Perception Questionnaire Revised, MINI MINI International Neuropsychiatric Interview, SAPAS Standardized Assessment of
Personality: Abbreviated Scale, SCL-90-R Symptom Checklist 90-Revised, SDS Sheehan Disability Scale, WHO-5 World Health Organization-Five
Well-being Index
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1 (disagree very much) to 5 (agree very much). The Ob-
tain Help from Community, Family, Friends subscale from
the Chronic Disease Self-Efficacy Scales consists of four
items about how confident the person feels in getting
emotional support and help with daily tasks from the
community, family and friends. The Control/Manage De-
pression subscale from the Chronic Disease Self-Efficacy
Scales consists of six items regarding how confident the
person feels about doing something to feel better when
feeling sad, discouraged or lonely. Each item on these two
subscales is rated on a 10-point Likert scale ranging from
1 (not at all confident) to 10 (very confident). The IN-
SPIRE questionnaire measures the patients’ feelings of be-
ing supported in their recovery by their primary health-
care provider(s). The questionnaire has two sections: one
assessing support from the health-care provider (20
items); and one assessing the relationship with the health-
care provider (seven items). General satisfaction with
treatment is assessed through the CSQ-8 questionnaire,
which consists of eight items rated on a scale ranging from
1 to 4. Information about sick leave and employment is
obtained from the Danish Register for Evaluation of
Marginalization (DREAM) database [62]. Information
about outpatient mental-health contacts is collected
through the National Patient Register, which contains in-
formation about all patient contacts in the secondary
health-care system [63].
Other data collection
Descriptive information about sex, age, housing and edu-
cation is collected through Statistics Denmark, which is
the central authority on Danish statistics [64]. Informa-
tion about workforce participation is collected through
the DREAM database [62]. Information about former
treatment for anxiety or depression is collected through
the National Patient Register [63] and information about
screening for personality disorder is based on the
Standardized Assessment of Personality (SAPAS) [41].
Collaborative care-specific data, such as use of
treatment modalities, number of step-ups and ses-
sions, will be registered by the Collabri Flex team
throughout the intervention period. Information about
consultations between the patient and GP will be reg-
istered in both the collaborative care and consultation
liaison group at 1, 3 and 6 months and patient-spe-
cific communication between professionals will be
registered continuously.
Safety measures
Safety measures are self-reported anxiety and depression
symptoms measured by the BAI [47] and BDI-II [44];
deaths from suicide and other causes collected through
the Danish Register of Causes of Death [65]; and somatic
inpatient and outpatient services and psychiatric
inpatient services obtained from the National Patient
Register [63].
Sample size and power calculations
The Collabri Flex Trial for Depression
Clinically relevant treatment response at group level is
defined as a 4-point difference in depression symptoms
measured by the BDI-II [66, 67]. At the time of sample
size calculation, we found no relevant Danish studies
that could contribute to the estimation of the within-
group standard deviation (SD) for the BDI-II in this
population. Therefore, the SD for the BDI-II is set to 11,
based on international surveys [66–68]. A sample size
calculation based on these figures shows that 240 partic-
ipants should be included to be able to reject the null
hypothesis that the collaborative care group and the
consultation liaison group have improved similarly in
terms of symptoms with a power of 0.8 and a signifi-
cance level of 0.05.
The Collabri Flex Trial for Anxiety
Clinically relevant treatment response is defined as a
4-point difference in anxiety symptoms measured
with the BAI. The estimation is based on studies
using the BDI [66, 67], because, to our knowledge,
there are no comparable Danish studies using the
BAI. Additionally, we could not find any Danish
studies that could contribute to the estimation of the
SD for the BAI in this population. Therefore, the SD
is set to 12 based on international surveys [68–70].
Based on these figures, the sample size calculation
shows that 284 individuals should be included in the
anxiety trial to be able to reject the null hypothesis
that the collaborative care group and the consult-
ation liaison group have improved similarly in terms
of anxiety symptoms with a power of 0.8 and a sig-
nificance level of 0.05.
Power calculations for the secondary outcomes
showed that 120 participants in each group in the de-
pression trial and 142 participants in each group in
the anxiety trial will be sufficient to detect relevant
significant differences in the secondary outcomes with
a power above 80% (see Tables 3 and 4). The power
calculations were performed subsequent to the sample
size calculations. Some of the figures are based on
Collabri data that were not available at the time of
sample size calculations.
Statistical analyses
The null hypothesis tested in both trials is that there is
no difference in depression and anxiety symptoms, re-
spectively, between the two groups (collaborative care
and consultation liaison) at 6 months’ follow-up. For
continuous outcomes, including the primary outcomes,
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analysis of variance (ANCOVA) will be used to exam-
ine differences between group means. For exploratory
binary outcomes, logistic regression analysis will be
used to detect differences between groups. All analyses
will be adjusted for stratification variables. The trials
will be conducted according to the statistical principle
“intention-to-treat”, which means that analyses will be
based on all included participants. If necessary, mul-
tiple imputations will be used to address the issue of
missing data.
Discussion
The design of the trials has several strengths. The
collaborative care model has been developed based on
previous experiences and with special emphasis on
meeting the needs of GPs. We hope this will increase
the success of any subsequent implementation; fidelity
reviews will be conducted to ensure faithfulness to the
intervention; we recognize the risk of contamination of
the control group when testing a system-level interven-
tion, and therefore we compare the collaborative care
group with a form of consultation liaison that equals
the contaminating elements; the randomization is ex-
ternally computer generated, which reduces the risk of
selection bias; compared with the Collabri trials, the
questionnaire battery has been shortened to enhance
the follow-up rate; and the psychiatrist in the Collabri
Flex team and many of the care managers and GPs also
participated in the previous Collabri trials, and, accord-
ingly, they have already worked within the framework
of the similar Collabri model and have experienced
being part of an RCT.
The design of the trials also has some limitations.
Most outcomes, including the primary outcomes, are
self-reported, which could lead to information bias
and, possibly, overestimation of effects [74]; partici-
pants, the Collabri Flex team and GPs are not blinded
to the allocation, which could lead to performance
bias; because we compare two active intervention
groups, it might be more difficult to detect a differ-
ence between groups than if we had compared collab-
orative care with treatment as usual; thus, accordingly,
from these trials we will not be able to conclude
whether collaborative care is more effective than treat-
ment as usual. However, the results will supplement
those of the cluster-randomized Collabri trials and
together they will provide pivotal information about
the effects of collaborative care in Denmark.
Trial status
The Collabri Flex Trial for Depression and the Col-
labri Flex Trial for Anxiety were initiated in mid-
January 2018. Recruitment is ongoing and expected to
end 12 months after trial initiation. The results are
expected after an additional 12 months. This protocol
is version 2.
Table 3 Power calculations for secondary outcomes in the depression trial
δ value for clinically
relevant difference
α value for
type I error
σ value for the
within-group SD
Calculated
power
Reference
BAI 4 0.05 (5%) 10 0.870 (87.0%) [66, 67] SD is based on data from the
Collabri depression trial (not published)
SDS 4 0.05 (5%) 9 0.930 (93.0%) [51, 52, 71]
SCL-90-R 23 0.05 (5%) 50 0.944 (94.4%) [72]
WHO-5 10 0.05 (5%) 18 0.990 (99.0%) [55, 73] SD is based on data from the
Collabri depression trial (not published)
BAI Beck Anxiety Inventory, SCL-90-R Symptom Checklist 90-Revised, SD standard deviation, SDS Sheehan Disability Scale, WHO-5 World Health Organization-Five
Well-being Index
Table 4 Power calculation for secondary outcomes in the anxiety trial
δ value for clinically
relevant difference
α value for
type I error
σ value for the
within-group SD
Calculated power Reference
BDI-II 4 0.05 (5%) 11 0.863 (86.3%) [66–69]
SDS 4 0.05 (5%) 10 0.920 (92.0%) [51, 52, 71]
SCL-90-R 23 0.05 (5%) 50 0.972 (97.2%) [72]
WHO-5 10 0.05 (5%) 26 0.898 (89.8%) [55, 73] SD is based on data from the
Collabri anxiety trial (not published)
BDI-II Beck Depression Inventory II, SCL-90-R Symptom Checklist 90-Revised, SD standard deviation, SDS Sheehan Disability Scale, WHO-5 World Health
Organization-Five Well-being Index
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